汇控(00005.HK)拟发20亿美元永久後偿或有可转换证券
汇控(00005.HK)公布,计划於3月9日发行总值10亿美元之之4厘永久後偿,或有可转换证券及10亿美元之4.7厘永久後偿或有可转换证券。
假设相关证券按其最初转换价被悉数转换,相关证券将被转换为约5.3亿股普通股,占公司之已发行股本约2.6%,以及发行此等转换股份後公司经扩大已发行股本约2.54%。初步定为每股转换股份3.77美元(约29.246港元)。
公司预计,发行相关证券所得款项的净额为19.8亿美元(约153.6亿港元),将用於再融资、一般公司事务及根据资本票据规例的规定维持或加强公司的资本基础。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.